Introducing the BeVigilant™ RAPID Platform
Transforming Detection. Improving Lives.™
Introducing the BeVigilant™ RAPID Platform
Transforming Detection. Improving Lives.™
The BeVigilant™ RAPID Test + RAPID Reader Easily Identifies the Presence of Biomarkers Associated with Oral Cancer in 10 Minutes.
The BeVigilant™ RAPID Test + RAPID Reader Easily Identifies the Presence of Biomarkers Associated with Oral Cancer in 10 Minutes.
The Vigilant Biosciences® BeVigilant™ RAPID Test is based on patented technology that assesses CD44, a tumor–initiating and stem cell–associated biomarker, and total protein levels–markers clinically validated to be associated specifically with oral cancer when tested in an oral rinse–to aid clinicians in the early detection of oral cancer. The simple, oral rinse procedure is easy to administer and non–invasive for the patient.
With the BeVigilant™ RAPID Platform, clinicians can get a simple and accurate† assessment to aid in the early detection of oral cancer (including oral and oropharyngeal cancer) potentially before lesions are visible. The BeVigilant RAPID Platform provides a qualitative result at the point–of–care, reporting either normal or elevated levels of oral cancer biomarkers.
With the BeVigilant™ RAPID Platform, clinicians can get a simple and accurate† assessment to aid in the early detection of oral cancer (including oral and oropharyngeal cancer) potentially before lesions are visible. The BeVigilant RAPID Platform provides a qualitative result at the point–of–care, reporting either normal or elevated levels of oral cancer biomarkers.
BeVigilant™ RAPID Test is an easy–to–use, accurate,† qualitative tool for frontline healthcare clinicians assessing potentially at–risk patients for oral cancer.
Provide test results during the patient visit with the BeVigilant™ RAPID Reader. This advanced immunochromatography reader captures the test data and uploads to the BeVigilant™ Portal for quick and effortless patient reporting.
View and monitor patients’ known risk–factors and test data in easy–to–read graphs and reports in the BeVigilant™ Portal.
BeVigilant™ RAPID Test is an easy–to–use, accurate,† qualitative tool for frontline healthcare clinicians assessing potentially at–risk patients for oral cancer.
Provide test results during the patient visit with the BeVigilant™ RAPID Reader. This advanced immunochromatography reader captures the test data and uploads to the BeVigilant™ Portal for quick and effortless patient reporting.
View and monitor patients’ known risk–factors and test data in easy–to–read graphs and reports in the BeVigilant™ Portal.
Play Video
CD44 is significantly overexpressed in oral cancer even in early stages.
The qualitative biomarker assay, BeVigilant™ RAPID Test, with a negative predictive value (NPV) of 92%1, performs well in ruling out oral cancer when a reasonable suspicion exists.
Created to improve outcomes through earlier intervention, the
BeVigilant™ RAPID Test is
ACCURATE†
NON-INVASIVE
FAST RESULTS IN
JUST 10 MINUTES
The BeVigilant™ RAPID Test is CE Marked and available in select markets outside the United States.
The BeVigilant™ RAPID Test Complements Regular Check-Ups for a More Comprehensive Oral Exam.
How It Works:
This saliva based test is non-invasive and easy to administer. The patient swishes and gargles sterile saline for 10 seconds, spits the saliva specimen in the collection cup and the clinician dips the BeVigilant RAPID Test in the saliva specimen. Results are read in 10 minutes!
The BeVigilant™ RAPID Platform includes the BeVigilant™ RAPID Test, RAPID Reader and BeVigilant™ Portal to provide a qualitative test result at the point-of-care, reporting either low or elevated risk levels of oral cancer biomarkers.
Quickly identify patients who may need additional follow–up
Advanced immunochromatography reader reporting test results during the patient visit
A web portal to store and track a patient’s results over time
Quickly identify patients who may need additional follow–up
Advanced immunochromatography reader reporting test results during the patient visit
A web portal to store and track a patient’s results over time
The BeVigilant™ RAPID Test + RAPID Reader is a value-added offering allowing clinicians to integrate easily into their practice as part of the patients’ regular care
The BeVigilant™ RAPID Test + RAPID Reader is a value-added offering allowing clinicians to integrate easily into their practice as part of the patients’ regular care
WANT TO LEARN MORE?
WANT TO LEARN MORE?
†Clinical Data on File
1With 95% CI of 84% – 96%
© 2020 Vigilant Biosciences